Table 2 Comparisons of inhaled dose between VMN and jet nebulizer via HFNC
From: A narrative review on trans-nasal pulmonary aerosol delivery
Publication | Study type | Population | Flow (L/min) | Inhaled dose (%) | |
|---|---|---|---|---|---|
JN | VMN | ||||
Réminiac et al., 2017 [38] | In vivo | Infant | 8 | 0.03 ± 0.03 | 0.09 ± 0.04 |
In vitro | 0.46 ± 0.12 | 0.52 ± 0.23 | |||
Ari, 2019 [33] | In vitro | Infant | 6 | 1.45 ± 0.10 | 2.35 ± 0.30 |
Pediatric | 6 | 2.46 ± 0.10 | 5.37 ± 0.70 | ||
Madney et al., 2019 [11] | In vivo | Adult | 5 | 7.90 ± 3.10 | 12.20 ± 4.40 |
Dugernier et al., 2017 [41] | In vivo | Adult | 30 | 1.0 (0.70–2.0) | 3.60 (2.10–4.40) |